Sphera Funds Management LTD. Has $2.77 Million Stake in Translate Bio Inc (TBIO)

Sphera Funds Management LTD. grew its stake in shares of Translate Bio Inc (NASDAQ:TBIO) by 112.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 276,639 shares of the company’s stock after purchasing an additional 146,639 shares during the period. Sphera Funds Management LTD. owned about 0.61% of Translate Bio worth $2,766,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC purchased a new stake in shares of Translate Bio during the second quarter valued at $73,437,000. Laurion Capital Management LP purchased a new stake in shares of Translate Bio during the second quarter valued at $822,000. Luminus Management LLC purchased a new stake in shares of Translate Bio during the second quarter valued at $1,925,000. Bain Capital Public Equity Management LLC purchased a new stake in shares of Translate Bio during the second quarter valued at $12,332,000. Finally, DAFNA Capital Management LLC purchased a new stake in shares of Translate Bio during the second quarter valued at $253,000. 49.48% of the stock is owned by institutional investors and hedge funds.

TBIO has been the subject of several analyst reports. ValuEngine raised Translate Bio from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Leerink Swann upped their price target on Translate Bio from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, November 14th.

NASDAQ:TBIO opened at $8.53 on Friday. Translate Bio Inc has a 1-year low of $5.00 and a 1-year high of $16.60. The company has a debt-to-equity ratio of 0.91, a quick ratio of 16.71 and a current ratio of 16.72.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-has-2-77-million-stake-in-translate-bio-inc-tbio.html.

Translate Bio Profile

Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.

Recommended Story: Cost of Capital

Institutional Ownership by Quarter for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply